BTIG analyst Julian Harrison downgraded Theravance Biopharma (NASDAQ: TBPH) from Buy to Neutral.The analyst comments "Zymeworks (ZYME, Not Rated) has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE